-

PerkinElmer Launches ChemDraw® V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft PowerPoint Reports

Ability to import 3D molecular models with one click accelerates information sharing, collaboration and decision making

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced V21 of its ChemDraw® software featuring the ability to import, animate and share 3D chemical structures natively in the Microsoft® PowerPoint® application with one click. The key enhancement, to a tool used by millions of scientists around the world, helps chemists create more intelligent research reports quickly and easily -- improving information sharing and collaboration and supporting real-time decision making.

Using the new ChemDraw V21 software, chemists simply paste a live 3D rendering of their molecule, with its atom and bond color highlights fully retained, natively into the Microsoft PowerPoint application where they can view, rotate and share the image. Researchers can also save molecules as 3D printable objects. No other chemical drawing application in the industry today provides these intuitive capabilities which eliminate the need to use specialized software with steep learning curves.

Part of the PerkinElmer® ChemOffice®+ Cloud platform, the software also continues to allow users to quickly perform chemical structure searches across disparate Microsoft documents and easily create reports of their chemistry experiments in PerkinElmer’s cloud-native Signals Notebook™ electronic lab notebook (ELN).

“ChemDraw software and the ChemOffice+ Cloud platform are all about simplifying, facilitating, and accelerating chemistry communication to transform drawings into shareable knowledge,” said Kevin Willoe, VP and GM of PerkinElmer Informatics. “With this latest ChemDraw software release, chemists working on new drugs or materials can go from a 2D to 3D world more efficiently and help drive fluid collaboration and data-rich, timely decision making.”

ChemDraw software is part of PerkinElmer’s extensive informatics portfolio which is used by more than 2 million scientists around the globe today. Pharmaceutical, agrochemical, advanced materials, and food industries rely on PerkinElmer’s cloud-based, electronic notebook and laboratory informatics solutions to capture, store and analyze research data, collaborate, and support data-driven R&D and clinical decisions.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Contacts

Media
Jennifer McNeil
Jennifer.Mcneil@perkinelmer.com
+1 508-380-2902

PerkinElmer, Inc.

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Summary
ChemDraw® V21 software supports import, animation and sharing of 3D chemical structures natively in Microsoft® PowerPoint® with one click.
Release Versions

Contacts

Media
Jennifer McNeil
Jennifer.Mcneil@perkinelmer.com
+1 508-380-2902

More News From PerkinElmer, Inc.

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for t...

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from disco...

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Inves...
Back to Newsroom